According to a separate interim analysis of the trial, treatment with T-DXd resulted in a 24.5% ORR in HER2-overexpressed, immunohistochemistry (IHC) 2+ or 3+, but HER2 mutation-negative NSCLC, a status that may partially correspond to HER2 amplification. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.